Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03331861 · ClinicalTrials.gov registry record · Phase 2
Metformin in Heart Failure Without Diabetes
A Phase 2 study, sponsored by Columbia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03331861: Clinical Trial Phase 2 study, sponsored by Columbia University.
NCT03331861 is a Phase 2 study that was terminated before completion, run by Columbia University. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03331861, a Phase 2 study, was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
A pilot clinical research study that will assess the use of the medication metformin for heart failure in patients who are not diabetic and have no evidence of insulin resistance.
Primary Outcome
The VO2 change outcomes will be assessed for normality using standard visual assessments (Q-Q plots and histograms) and statistical tests (Kolmogorov-Smirnov). VE/VCO2 slope change will be calculated.
Interventions
- DRUG Placebo
- DRUG Metformin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-02-15 |
| Est. Completion | 2021-08-20 |
| Phase | Phase 2 |
Why NCT03331861 stopped before completion
NCT03331861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03331861 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03331861 about?
NCT03331861 is a clinical study titled "Metformin in Heart Failure Without Diabetes". A pilot clinical research study that will assess the use of the medication metformin for heart failure in patients who are not diabetic and have no evidence of insulin resistance.
What is the current status of trial NCT03331861?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-02-15. Estimated completion is 2021-08-20.
What interventions are being tested in trial NCT03331861?
The interventions under investigation include: Placebo (DRUG), Metformin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03331861?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03331861's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI